News
ASCO 25: Braftovi shows "unprecedented" survival gain
A combination regimen based on Pfizer's BRAF inhibitor Braftovi …
20933 items found
R&D
Bringing patients to research centres: Using AI to bring efficiencies forward
Trends can be predicted, and trends can unfold. Here, Liz Beatty – …
Oncology
Innovation, real-world data, and precision medicine: Pierre Fabre and the lung cancer space
As ASCO 2025 kicks off in Chicago, pharmaphorum looks back to a …
Oncology
AACR 2025: New modalities and remaining challenges
Talk elsewhere might have been of Trump’s tariffs lately, but the …
News
Summit shrugs off survival miss with its VEGF bispecific
Summit Pharma has revealed that a second pivotal trial of its …
News
Astellas adds to claudin clout with $1.3bn+ Evopoint deal
Astellas was the first company to bring a drug against the claudin …
News
Roche builds case for MS drug with two-year efficacy data
Roche has revealed new results from a phase 2 trial of its oral BTK …
News
Axe falls on Stealth Bio staff after FDA rejects lead drug
Stealth BioTherapeutics' filing for rare disease drug elamipretide …
News
GRIN raises $140m for epilepsy drug, and other financings
Our round-up of recent biotech financings is headed by a $140 million …
News
MSD and Daiichi Sankyo pull HER3-DXd's FDA filing
A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug …
News
Old COVID tweet lands Pfizer in new trouble with PMCPA
Pfizer has been found to be in breach of the UK pharma industry's …
News
Moderna's $760m-plus flu vaccine contracts are nixed by HHS
In January, Moderna was celebrating a $590 million contract with the …
News
ASCO 25: Braftovi shows "unprecedented" survival gain
Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in the BREAKWATER trial, setting up full FDA approval.
Market Access
Sponsored
Bridging research and clinical guidelines – interactive stra...
Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
R&D
Deep Dive: Research and Development 2025
Every breakthrough in medicine, every new treatment that changes lives, starts with research.
R&D
Life Sciences Industry Report - Biologics and Generics
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Oncology
Life Sciences Industry Report - Oncology
Developments in the oncology space in 2024 brought hope to both industry and patients.
Digital
Partner Content
Axtria Ignite 2025: Leading in an Agentic Era
Axtria’s flagship event is almost here! Axtria Ignite 2025 is taking place 4th to 5th June at the Princeton Marriott at Forrestal in New Jersey. This
Patients
Partner Content
Operationalize: Expanded Access Programs comes to the West C...
Improving Global Access to Life-Changing Therapeutics...